Brief: Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals For Anticipated Launch Of ATI-1501 Antibiotic Candidate In The U.S.
03/12/2019 12:56
Dec 3 (Reuters) - Appili Therapeutics Inc APLI.V :
* APPILI THERAPEUTICS ENTERS COMMERCIAL AGREEMENT WITH
SAPTALIS
PHARMACEUTICALS FOR ANTICIPATED LAUNCH OF ATI-1501 ANTIBIOTIC
CANDIDATE IN THE U.S.
* APPILI THERAPEUTICS INC - NDA FILING EXPECTED WITHIN 18
MONTHS
FOR LIQUID METRONIDAZOLE
* APPILI THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, APPILI
IS
ELIGIBLE TO RECEIVE MULTIPLE MILESTONE AND ROYALTY PAYMENTS ON
SALE OF ATI-1501 IN U.S.
* APPILI THERAPEUTICS INC - SAPTALIS TO OVERSEE REGULATORY
REVIEW,
MANUFACTURING, PREPARATION FOR ANTICIPATED COMMERCIALIZATION OF
ATI-1501 IN U.S
Source text for Eikon: ID:nBwpxT6Za
Further company coverage: APLI.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez